Abstract
The use of stem cells to repair and replace damaged skeletal muscle cells in chronic, debilitating muscle diseases such as the muscular dystrophies holds great promise. Different stem cell populations, both of embryonic and adult origin display the potential to generate skeletal muscle cells and have been studied in animal models of muscular dystrophy. These include muscle derived satellite cells; bone marrow derived mesenchymal stem cells, muscle or bone marrow side population cells, circulating CD133+ cells and cells derived from blood vessel walls such as mesoangioblasts or pericytes. The design of effective stem cell based therapies requires a detailed understanding of the molecules and signaling pathways which determine myogenic lineage commitment and differentiation. We discuss the great strides that have been made in delineating these pathways and how a better understanding of muscle stem cell biology has the potential to lead to more effective stem cell based therapies for skeletal muscle regeneration for devastating muscle diseases.
Keywords: Skeletal Muscle Diseases, stem cells, muscular dystrophies, mesenchymal stem cells, mesoangioblasts, myogenesis
Current Stem Cell Research & Therapy
Title: Stem Cell Based Therapy for Skeletal Muscle Diseases
Volume: 3 Issue: 3
Author(s): Satyakam Bhagavati
Affiliation:
Keywords: Skeletal Muscle Diseases, stem cells, muscular dystrophies, mesenchymal stem cells, mesoangioblasts, myogenesis
Abstract: The use of stem cells to repair and replace damaged skeletal muscle cells in chronic, debilitating muscle diseases such as the muscular dystrophies holds great promise. Different stem cell populations, both of embryonic and adult origin display the potential to generate skeletal muscle cells and have been studied in animal models of muscular dystrophy. These include muscle derived satellite cells; bone marrow derived mesenchymal stem cells, muscle or bone marrow side population cells, circulating CD133+ cells and cells derived from blood vessel walls such as mesoangioblasts or pericytes. The design of effective stem cell based therapies requires a detailed understanding of the molecules and signaling pathways which determine myogenic lineage commitment and differentiation. We discuss the great strides that have been made in delineating these pathways and how a better understanding of muscle stem cell biology has the potential to lead to more effective stem cell based therapies for skeletal muscle regeneration for devastating muscle diseases.
Export Options
About this article
Cite this article as:
Bhagavati Satyakam, Stem Cell Based Therapy for Skeletal Muscle Diseases, Current Stem Cell Research & Therapy 2008; 3 (3) . https://dx.doi.org/10.2174/157488808785740343
DOI https://dx.doi.org/10.2174/157488808785740343 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
Call for Papers in Thematic Issues
Molecular Mechanisms and Translational Strategies Targeting the Disease Immune Microenvironment
This thematic issue aims to highlight recent advances in deciphering the molecular mechanisms underlying the disease immune microenvironment, with a particular focus on cancer and chronic inflammatory conditions. It will bring together cutting-edge research in immune regulation, biomarker discovery, epigenetic remodeling, and post-translational modifications that influence disease progression and therapeutic ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets Therapeutic Strategy of Erythropoietin in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Current Management of Fetal and Neonatal Renal Tumors
Current Pediatric Reviews subject Index To Volume 2
Current Pharmaceutical Biotechnology Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer
Current Cancer Drug Targets Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals Rituximab The First Monoclonal Antibody Approved for the Treatment of Lymphoma
Current Pharmaceutical Biotechnology Single Autosomal Trisomy in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Current Genomics Receptor Tyrosine Kinases as Therapeutic Targets in Malignant Glioma
Reviews on Recent Clinical Trials DNA Tetraplex-Binding Drugs Structure-Selective Targeting is Critical for Antitumour Telomerase Inhibition
Mini-Reviews in Medicinal Chemistry Use of Recombinant Human Erythropoietin as an Antianemic and Performance Enhancing Drug
Current Pharmaceutical Biotechnology Stem Cells as a Novel Tool for Drug Screening and Treatment of Degenerative Diseases
Current Pharmaceutical Design ASPM Predicts Poor Clinical Outcome and Promotes Tumorigenesis for Diffuse Large B-cell Lymphoma
Current Cancer Drug Targets Pulmonary Arterial Hypertension in HIV-infected Patients
Current Hypertension Reviews Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry The Role of 5-Hydroxymethylcytosine in Aging and Alzheimer’s Disease: Current Status and Prospects for Future Studies
Current Alzheimer Research Last Findings on Dual Inhibitors of Abl and Src Tyrosine-Kinases
Mini-Reviews in Medicinal Chemistry Recent Progress and Related Patents on the Applications of Bone Marrow-Derived Stem/Progenitor Cells in Regenerative Medicine and Cancer Therapies
Recent Patents on Regenerative Medicine Strategies for Increasing the Solubility and Bioavailability of Anticancer Compounds: β-Lapachone and Other Naphthoquinones
Current Pharmaceutical Design Channel-Like Functions of the 18-kDa Translocator Protein (TSPO): Regulation of Apoptosis and Steroidogenesis as Part of the Host-Defense Response
Current Pharmaceutical Design